Joincare(SH:600380)2024-10-24 08:26Financial Performance - Q3 2024 revenue was approximately ¥3.66 billion, a decrease of 6.80% year-over-year, while year-to-date revenue reached about ¥11.90 billion, down 5.95% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was approximately ¥335.14 million, an increase of 24.95% year-over-year, with year-to-date net profit at about ¥1.11 billion, up 2.58%[2]. - Basic earnings per share for Q3 2024 was ¥0.18, reflecting a 26.01% increase year-over-year, while diluted earnings per share also stood at ¥0.18, up 26.79%[2]. - Total operating revenue for the first three quarters of 2024 was CNY 11,898,828,905.02, a decrease of 5.94% compared to CNY 12,651,257,386.44 in the same period of 2023[14]. - Operating profit increased to CNY 2,832,383,097.69, up 5.06% from CNY 2,696,081,778.73 year-on-year[14]. - Net profit attributable to shareholders of the parent company was CNY 1,111,560,063.92, representing a growth of 2.93% compared to CNY 1,083,649,154.75 in the previous year[14]. - The total comprehensive income attributable to the parent company for Q3 2024 was CNY 1,052,190,204.75, a decrease from CNY 1,084,654,915.15 in Q3 2023, reflecting a decline of approximately 3%[16]. Assets and Liabilities - Total assets as of September 30, 2024, were approximately ¥36.17 billion, a decrease of 0.51% from the end of the previous year[3]. - Total assets as of September 30, 2024, were CNY 36,172,500,281.87, slightly down from CNY 36,358,126,258.82 at the end of 2023[13]. - Total liabilities decreased to CNY 12,627,521,547.15 from CNY 13,718,595,768.18 at the end of 2023, reflecting a reduction of 7.96%[13]. - The company’s total equity increased to CNY 23,544,978,734.72 from CNY 22,639,530,490.64 at the end of 2023, reflecting a growth of 4.00%[13]. Cash Flow - The company reported a net cash flow from operating activities of approximately ¥2.61 billion for the year-to-date, an increase of 6.25% compared to the previous year[2]. - Cash flow from operating activities for the first nine months of 2024 was CNY 2,613,605,501.06, compared to CNY 2,459,851,744.70 in the same period of 2023, representing an increase of about 6.2%[17]. - The net cash flow from investing activities for the first nine months of 2024 was -CNY 1,183,961,052.92, worsening from -CNY 675,752,976.46 in the same period of 2023[17]. - The net cash flow from financing activities for the first nine months of 2024 was -CNY 2,147,617,457.61, compared to -CNY 1,987,651,014.91 in the previous year, indicating a decline of about 8%[18]. - The company’s cash outflow for operating activities was CNY 10,853,237,087.15 in the first nine months of 2024, compared to CNY 11,812,825,647.33 in the previous year, reflecting a decrease of approximately 8.1%[17]. - The company experienced a foreign exchange loss affecting cash and cash equivalents, amounting to -CNY 37,426,542.59 in Q3 2024, contrasting with a gain of CNY 71,991,155.94 in Q3 2023[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 76,823[8]. - Shenzhen Baiye Yuan Investment Co., Ltd. holds 895,653,653 shares, accounting for 47.79% of the total shares[8]. - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest shareholder holding nearly half[8]. - The company has no significant changes in the shareholding structure due to margin trading or stock lending activities[10]. - The report indicates that there are no related party transactions among the top shareholders[9]. - The company has a total of 20,006,912 shares held by China Agricultural Bank Co., Ltd. - CSI 500 ETF, representing 1.07% of the total shares[10]. - The company has 12,502,378 shares held by the Abu Dhabi Investment Authority, accounting for 0.67%[9]. Operational Insights - Revenue from chemical preparations for the first nine months of 2024 was approximately ¥5.88 billion, a decline of 10.55% year-over-year, with specific product categories showing varied performance[3]. - The company experienced a significant increase in health food revenue, which grew by 97.67% year-over-year to approximately ¥262 million[3]. - Research and development expenses for the first three quarters amounted to CNY 1,036,376,310.06, down 14.45% from CNY 1,211,596,866.40 in the same period last year[14]. - The report does not indicate any significant operational issues during the reporting period[11]. - There are no audit opinion types applicable for the financial statements in this quarter[11]. - The company has not disclosed any new strategies or product developments in this report[11].